Lexaria Bioscience Corp.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a biotechnology company that develops and commercializes its patented DehydraTECH drug delivery platform technology. DehydraTECH combines active pharmaceutical ingredients with long-chain fatty acid-rich triglyceride oils and carrier compounds to improve bloodstream absorption, increase effectiveness, enable lower dosing, and support healthier oral ingestion methods. The technology applies to ingestible and topical formats including oral suspensions, tablets, capsules, foods, beverages, and other products. Lexaria maintains an in-house formulation development and research laboratory and holds a portfolio of 65 granted patents worldwide.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Recent private placement and equity financings provided $7.9 million in total proceeds extending cash runway through 2027.
- Company plans no further equity or debt raises in 2026 and will rely more on business development partners for R&D funding.
- DehydraTECH technology improves API absorption for lower dosing and better tolerability across multiple delivery formats.
- Lexaria holds 65 granted patents and operates an in-house formulation laboratory to support ongoing R&D.
Ask StreetZero about Lexaria Bioscience Corp.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account